Parents face prison terms for neglecting son with Hodgkin's
When eight-year-old William Robinson of Ohio died from Hodgkin's lymphoma and pneumonia in 2008, a county coroner ruled the boy's death a homicide. A year later, his parents Monica Hussing, 37, and William Robinson Sr, 40, were indicted for medical neglect because they failed to seek treatment for their son, despite the fact that Hodgkin's lymphoma has one of the highest cure rates of any cancer.
Upon being arrested, the Ohio parents lost custody of their five other children. On Monday, each of the parents pleaded guilty to a single count of attempted involuntary manslaughter. Based on their pleas, the two are now facing eight years in prison.
In a baffling and sickening twist, Hussing and Robinson have admitted that while their son was dying from Hodgkin's, the two sought treatment for a flea problem developed by a recently adopted pit bull.
They will be sentenced on February 16; until then, they remain free on bail.
Source: Reuters
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
